Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DC This is why we think Radient is going to merge with Provista Diagnostics.. Here is the story..Just follow it..The agreement was signed sealed and delivered...William is Vice President of Development with Provista Diagnostics. He is developing their lung cancer test incognito.....Under the guise of GCDX...The company is real and can be transferred to PDX and be used as a subsidiary. DR-70 alone is not a good reagent according to all in this forum. This is all you need to know to know what to know you understand,,,William's intentions and recent actions have shown that he is going by this plan..If someone says the agreement needed to be listed in a 8-k..They are dead wrong..Mac kept this Ace in the hole close to his side...All one man's opinion you understand..Wolf ahooololoooooo

http://www.sec.gov/Archives/edgar/data/838879/000114420412039787/v318772_8k.htm

"Three months after the date of reversion, we will be entitled to enter new contractual agreements with third parties with regard to such rights."

NO OTHER THIRD PARTIES GOT THOSE RIGHTS EXCEPT UNI-PHARMA in CERTAIN Territories...


The Agreement contains non-compete and confidentiality terms regarding the Licensed Products, the latter of which expires 5 years after the Agreement terminates.

Although GCDx will pay all costs related to developing the Licensed Products for commercial applications, including process development costs, clinical study costs and costs related to the FDA filing and approval process, the parties agreed that GCDx shall pay us $150 per hour for any additional services GCDx requests above those services initially contemplated to carry out this development.